Development of a Curcumin-Loaded Polymeric Microparticulate Oral Drug Delivery System for Colon Targeting by Quality-by-Design Approach

The purpose of this study was to apply the quality-by-design (QbD) approach for the development of colon-targeted curcumin-loaded polymeric microparticles (Col-CUR-MPs). The proportion of the enterosoluble polymer (Eudragit<sup>®</sup> FS) in the polymeric matrix, curcumin concentration,...

Full description

Saved in:
Bibliographic Details
Main Authors: Dana Hales (Author), Lucia Ruxandra Tefas (Author), Ioan Tomuță (Author), Cristian Moldovan (Author), Diana Gulei (Author), Raluca Munteanu (Author), Alina Porfire (Author)
Format: Book
Published: MDPI AG, 2020-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8373e719f9ab4fbfbcdb69e2d75b02fb
042 |a dc 
100 1 0 |a Dana Hales  |e author 
700 1 0 |a Lucia Ruxandra Tefas  |e author 
700 1 0 |a Ioan Tomuță  |e author 
700 1 0 |a Cristian Moldovan  |e author 
700 1 0 |a Diana Gulei  |e author 
700 1 0 |a Raluca Munteanu  |e author 
700 1 0 |a Alina Porfire  |e author 
245 0 0 |a Development of a Curcumin-Loaded Polymeric Microparticulate Oral Drug Delivery System for Colon Targeting by Quality-by-Design Approach 
260 |b MDPI AG,   |c 2020-10-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics12111027 
500 |a 1999-4923 
520 |a The purpose of this study was to apply the quality-by-design (QbD) approach for the development of colon-targeted curcumin-loaded polymeric microparticles (Col-CUR-MPs). The proportion of the enterosoluble polymer (Eudragit<sup>®</sup> FS) in the polymeric matrix, curcumin concentration, and the concentration of the polymer mixture (Eudragit<sup>®</sup> FS-polycaprolactone) were identified as potential risk factors for the quality of the final product following risk assessment. The influence of these variables on the critical quality attributes (CQAs) of Col-CUR-MPs was investigated. Therefore, a central composite face experimental design was used in order to determine the functional relationships between variables and product CQAs. The obtained regression model and contour plots were used to establish the design space. Finally, the model was validated by preparing two microparticulate formulations, one corresponding to the robust setpoint from within the design space and one outside the established design space, and calculating the percentage bias between the experimental and predicted values. The in vivo study, which was conducted on a fluorescein-loaded formulation that corresponded to the robust setpoint determined by QbD and that contained a mixture of polycaprolactone and Eudragit<sup>®</sup> FS (60:40, <i>w/w</i>), confirmed the colon-targeting qualities of this formulation. 
546 |a EN 
690 |a curcumin 
690 |a Eudragit<sup>®</sup> FS 
690 |a polycaprolactone 
690 |a microspheres 
690 |a colon-specific delivery 
690 |a quality-by-design 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 12, Iss 11, p 1027 (2020) 
787 0 |n https://www.mdpi.com/1999-4923/12/11/1027 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/8373e719f9ab4fbfbcdb69e2d75b02fb  |z Connect to this object online.